What is Noxopharm Limited (NOXOF)?

Noxopharm Limited (NOXOF) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of NOXOF?

The current price of NOXOF is $0.05. Prices are updated in real time on Stocks360.

What is NOXOF's price-to-earnings (PE) ratio?

NOXOF's trailing twelve-month PE ratio is -5.25, based on current price and earnings per share data available on Stocks360.

What is NOXOF's market capitalization?

NOXOF's market capitalization is $14,781,601.00, placing it in the small-cap tier.

Noxopharm Limited (NOXOF)

Stock analysis · OTC · Healthcare · Biotechnology

$0.05

Market Cap

$14.78M

PE (TTM)

-5.25

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.14

Day Range

$0.05 – $0.05

52-wk Range

$0.05 – $0.05

Avg Volume

N/A

Volume

2.30K

Noxopharm Limited (NOXOF) is a publicly traded company in the Healthcare sector. Latest price: $0.05. Market cap $14.78M. Trailing PE -5.25. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Proprietary Signals

Signal snapshot temporarily unavailable.

About Noxopharm Limited

Noxopharm Limited, a pharmaceutical company, is focused on developing therapeutic solutions for a range of solid tumor cancers and septic shock, catering to both Australian and international markets. Its primary asset, Veyonda, is currently being developed as an adjuvant therapy, intended to complement chemotherapy and radiotherapy in the treatment of late-stage cancers. The company's robust pipeline includes several programs: The DARRT program, currently in Phase 1b/2a, targets metastatic castration-resistant prostate cancer and other solid tumor types. LuPIN investigates a combined therapy of Veyonda with 177Lu-PSMA-617 for managing late-stage prostate cancer. The IONIC program explores Veyonda in combination with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, for various solid tumor indications. Its Chemotherapy Enhancement Program (CEP) utilizes Veyonda alongside carboplatin to treat refractory solid tumors found in the breast, head and neck, lung, prostate, and ovaries. Beyond oncology, Noxopharm is advancing the NOXCOVID Program, a dose escalation and expansion study of NOX66, aimed at treating COVID-19 infections. Additionally, the company is pursuing early-stage prog…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-5.25×
P/S (TTM)	8.76×
P/B	3.40×
P/FCF (TTM)	-30.72×
EV / EBITDA	-4.07×
EV / Sales	7.79×
Earnings Yield	-19.13%
Free Cash Flow Yield	-3.25%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$18.70M
Revenue (TTM)	$2.40M
Net Income (TTM)	-$4.02M
Free Cash Flow (TTM)	-$653.15K
Net Debt	-$2.32M
Working Capital	$3.52M
Gross Margin	-22.28%
Operating Margin	-313.92%
Net Margin	-149.07%
Return on Equity	-49.12%
Return on Invested Capital	-136.08%